Humacyte (HUMA) Receivables (2020 - 2026)

Humacyte (HUMA) has reported Receivables for 5 consecutive years, with $330000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables fell 16.24% year-over-year to $330000.0 in Q2 2026; TTM through Jun 2026 was $330000.0, a 16.24% decrease from a year earlier, with the FY2025 full-year figure at $441000.0, up 145.0% from the prior year.
• Receivables was $330000.0 for Q2 2026 at Humacyte, down from $434000.0 in the prior quarter.
• Over five years, Receivables peaked at $1.3 million in Q2 2022 and troughed at $31000.0 in Q3 2022.
• A 3-year average of $476100.0 and a median of $414000.0 in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables tumbled 87.08% in 2022 and decreased 11.07% in 2026, its largest moves.
• Over 3 years, Receivables stood at $31000.0 in 2022, then jumped by 1322.58% to $441000.0 in 2025, then slipped by 25.17% to $330000.0 in 2026.
• The last three Receivables figures came in at $330000.0 (Q2 2026), $434000.0 (Q1 2026), and $441000.0 (Q4 2025), per Business Quant data.